Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCBT with non-myeloablative conditioning for hematological malignancies
NCT00719849Phase 2Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Nov 2005
- Primary completion
- Nov 2008
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of umbilical cord blood-derived regulatory T cells in leukemia, lymphoma, multiple myeloma (MM) and 3 more, sponsored by Fred Hutchinson Cancer Center. Started Nov 2005; status: terminated.
02
Drugs
umbilical cord blood-derived regulatory T cells
03
Conditions
leukemialymphomamultiple myeloma (MM)plasma cell neoplasmmyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00719849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00719849.